Get the detailed impact analysis of COVID-19 that has disrupted the entire world and affected many industries.
Request Insights
IN THE NEWSJanuary 27, 2022: Lonza Group to collaborate with HaemaLogiX Ltd., to manufacture next clinical batch of multiple myeloma drug candidate, KappaMab.
December 08, 2021: ThermoGenesis Holdings, Inc. to join hands with Contract Development Manufacturing Organization (CDMO) to make Cell and Gene therapies available to the maximum patients.
The global plasma expressor machine market is estimated to grow at a robust CAGR over the forecast period, i.e., 2022 – 2031. Plasma expressor machine is a device used to separate plasma, RBC, WBC and platelets from the blood. Basically, it is used for easy and efficient blood component separation in any manner. Various diseases, such as, leukopenia or neutropenia require only the white blood cells, while dengue treatment requires platelets separately. The growth of the market can be attributed to the growing need for any specific component of blood to treat various rare diseases. Blood cancer, such as, leukemia, lymphoma, and myeloma, are the primary disorders which entail the need for plasma expressor machines.
Moreover, the growing prevalence of blood cancer is estimated to boost the market growth. As per the data by the World Cancer Research Fund (WCRF), an estimated 18.1 million cancer cases were diagnosed around the world in 2020. Out of these, 18,094,716 new cancer cases were reported in 2020 itself. Among these, leukemia accounted for 474,519 cases, Hodgkin lymphoma accounted for 83,087 cases, and multiple myeloma accounted for 176,404 cases globally. CLICK TO DOWNLOAD SAMPLE REPORT
The market is segmented by application into plasma separation, chemical research, blood testing, pharmaceutical research, and others, out of which, the plasma separation segment is anticipated to hold a substantial share in the global plasma expressor machine market over the forecast period on account of increasing demand for plasma transfusion for treatment of pneumonia caused by coronavirus infection. Certain chronic conditions, such as, disseminated intravascular coagulation (DIC), also requires plasma transfusion. Such factors are estimated to boost the segment growth.
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
On the basis of geographical analysis, the global plasma expressor machine market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in the North America region is anticipated to gain the largest market share throughout the forecast period on the account of the high prevalence of leukemia and lymphoma in the region. According to the data by the American Cancer Society, in the United States, about 60,650 new cases of leukemia were reported in 2021, out of which, 20,050 cases of acute myeloid leukemia (AML) were reported. The market in the Asia Pacific region is anticipated to gain the largest market share throughout the forecast period growing incidences of blood cancer, along with rising health awareness amongst the people. Moreover, the increasing adoption of advanced medical technology, such as plasma expressor machine, is further estimated to boost the market growth.
The global plasma expressor machine market is further classified on the basis of region as follows:
North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
Our in-depth analysis of the global plasma expressor machine market includes the following segments:
FREQUENTLY ASKED QUESTIONS
Increasing prevalence of blood cancer, and other disorders is estimated to boost the market growth
The market is anticipated to attain a robust CAGR over the forecast period, i.e., 2022 – 2031.
High maintenance cost and limited availability of advanced technology in low-income regions are estimated to hamper the market growth.
The North America region is anticipated to provide more business opportunities over the forecast period on the back of growing incidences of blood cancer in the region.
The major players in the market are Escape Therapeutics, Inc., Regen BioPharma, Inc., ThermoGenesis Holdings, Inc., CSG-BIO Company, Inc. (CellSave), CBR Systems, Inc., Pluristem Inc., ViaCord, LLC, and Cynata Therapeutics Limited.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by type, application, end-user, and by region.
The hospital segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.
Related Reports
Disclaimer | Privacy Policy | Terms & Conditions
Copyright © 2021 Research Nester. All Rights Reserved
